Republican Rep. Chris Collins is under investigation for his alleged role in pushing stocks from an Australian pharmaceutical company, the Buffalo News reported Tuesday. Collins, who represents part of western New York, has reportedly been the subject of at least four ethics complaints this year, after news broke that he amended an FDA bill to include language favorable to Innate Immunotherapeutics, an Australian pharmaceutical company in which he had purchased $2.2 million in stock. After the bill was signed into law, Collins purchased another million in Innate stock. Collins did not disclose his investment, claiming protection from doing so under an inside-trading loophole that only requires members of Congress to disclose investments in U.S. stocks, The Daily Beast previously reported.
TOP 10 RIGHT NOW
SHOP WITH SCOUTED